Navigation Links
Alexza to Webcast Investor and Analyst Day Presentations
Date:4/22/2008

eventDetails&c=196151&eventID=1831771

or

http://www.alexza.com/investor_section/news_events.php

How: Live over the Internet -- Simply log on to the Web at the

address above and register for the event (approximately 10

minutes beforehand)

If you are unable to participate during the live webcast, the call will be archived on Alexza's website at http://www.alexza.com.

About Alexza Pharmaceuticals

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Stacca
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
2. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference
3. Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System
4. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
5. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
6. Johnson & Johnson to Webcast Annual Meeting of Shareholders
7. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
8. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2008 Financial Results
9. ResMed to Webcast Third Quarter 2008 Earnings Conference Call
10. CTG Announces 2008 First Quarter Conference Call and Webcast Information
11. MSA Schedules First Quarter Earnings Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Although there are only 24 hours in a day, ... have trouble finding time within their busy schedules for exercise and ... of time to get in shape. Here are five ways you ... , Change Up Your Commute , Consider riding a bike ... exercise into your daily routine. If you must use your car ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... Two sisters in high school have developed ways to ... Krishen use electronic stethoscopes, which electronically amplify body sounds, ... or heartbeats. Ilina, a senior at Port Huron ... way to detect early lung damage in people exposed ... recorded one breath cycle each from 16 smokers, 25 ...
(Date:10/22/2014)... -- Measures taken by Firestone officials at the company,s ... limited the spread of the disease there and could ... Rubber Co. provides health services to about 80,000 employees, ... communities. Between Aug. 1 and Sept. 23, there ... 80,000 people. That incidence rate of 0.09 percent was ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
... American Heart Association extend their sympathy to the family and friends ... , "It,s a shame when someone his age dies so ... "Although we don,t know all the details of the situation, ... react quickly. Our thoughts and prayers are with the Jackson ...
... BOTHELL, Wash., June 25 Verathon(R), the maker of BladderScan(R) ... company,s selection, for the third year in a row, as ... State. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20061011/SFW044LOGO ) , ... for 16th "Best Company To Work For" in the mid-size ...
... Association said Thursday that pop singer Michael Jackson,s death at ... arrest, which kills nearly 300,000 Americans each year and is ... cardiac arrest (SCA) is the result of an electrical disruption ... It can strike seemingly healthy individuals without warning, including ...
... warns of potential shortage of one pain reliever , THURSDAY, ... and drug ingredients at a Michigan-based manufacturer by the U.S. ... a particular type of pain reliever, the agency said on ... products from plants run by Caraco Pharmaceutical Laboratories Ltd in ...
... ... , ... (PRWEB) June 25, 2009 -- Two grocery checkers--a 28-year-old female triathlete and a 53-year-old ... identical. Which employee will return to work sooner? Is there anything you can do ...
... Providence Service Corporation (Nasdaq: PRSC ) today ... Inc., have certified the voting results of the Company,s ... preliminary results reported by Providence on June 15, 2009. ... a wide margin, re-elected to the Providence Board of ...
Cached Medicine News:Health News:American Heart Association Extends Sympathy to Family of Singer Michael Jackson 2Health News:Verathon Recognized, Third Year in a Row, as Outstanding Workplace in Washington State 2Health News:FDA Seizes All Drugs From Generics Maker 2Health News:MDGuidelines Offers New Predictive Modeling Feature 2Health News:MDGuidelines Offers New Predictive Modeling Feature 3Health News:MDGuidelines Offers New Predictive Modeling Feature 4Health News:Providence Service Corporation Announces Certified Voting Results of Annual Meeting of Stockholders 2Health News:Providence Service Corporation Announces Certified Voting Results of Annual Meeting of Stockholders 3
(Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
Medicine Products: